Stay updated with breaking news from Data Contribution Agreement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
C-Path and Tufts Medical Center have announced a joint venture to integrate the first patient-level clinical trial data to generate actionable real-world evidence for neonatal drug development, from real-world neonate data. This activity, funded by the FDA, is being executed through a neonatal pilot project within C-Path's International Neonatal Consortium.
(1) STOCKHOLM, Dec. 16, 2020 /PRNewswire/ -- Diamyd Medical and the Critical Path Institute (C-Path) are proud to announce their collaboration to significantly improve the scientific community's insight into type 1 diabetes (T1D) through Diamyd Medical's contribution of fully anonymized data from a European Phase III trial to the Trial Outcome Measures Initiative (TOMI) T1D integrated database. The Phase III trial evaluated the use of the diabetes vaccine Diamyd , an antigen-specific immunotherapy based on the auto-antigen GAD (glutamic acid decarboxylase), to induce immunological tolerance ...